Late-Start Menopause Hormone Therapy

What Does the Timing Hypothesis Say About Hormone Therapy?

The timing hypothesis emerged after the landmark Women's Health Initiative (WHI) trial published its first findings in the early 2000s. Researchers observed that the cardiovascular risks attributed to combined hormone therapy were concentrated in older women who initiated treatment many years after menopause, while younger women starting closer to the menopausal transition appeared to experience neutral or even favorable outcomes.

According to the new systematic review summarized in EMJ, this hypothesis remains the most clinically useful framework for counselling patients today. When estrogen, with or without a progestogen, is introduced to arteries that have already developed atherosclerotic changes, it may destabilise existing plaques rather than protect against new ones. In contrast, healthier vasculature in recently menopausal women appears more responsive to the vasodilatory and lipid-modifying effects of estrogen.

What Are the Cardiovascular Risks of Starting Hormone Therapy After 60?

The systematic review collates data showing that women who begin hormone therapy late face a less favourable risk-benefit balance. Stroke risk, particularly ischemic stroke, appears elevated when oral estrogen is started in this population, and venous thromboembolism remains a recognised concern across all ages but with greater absolute risk in older women due to baseline vascular changes.

Clinical guidance from organisations including the North American Menopause Society and the International Menopause Society has long advised caution when considering MHT in women more than 10 years past menopause. The EMJ review reinforces these positions and highlights that transdermal estrogen formulations may carry a more favourable thrombotic profile than oral preparations, although robust randomised data in late-initiation populations remain limited.

When Should Older Women Consider Hormone Therapy at All?

Despite the cardiovascular concerns, some women in their sixties and beyond continue to experience hot flashes, night sweats, and genitourinary symptoms severe enough to disrupt sleep, mood, and quality of life. For these patients, clinicians may consider low-dose transdermal estrogen, ideally at the lowest effective dose and for the shortest necessary duration, after screening for cardiovascular risk factors, prior thrombotic events, and breast cancer history.

Vaginal estrogen, used purely for genitourinary syndrome of menopause, is generally regarded as safe at any age because systemic absorption is minimal. Non-hormonal alternatives such as SSRIs, SNRIs, gabapentin, and the newer neurokinin-3 receptor antagonists like fezolinetant offer additional options for women in whom systemic MHT is contraindicated or undesirable.